Clinical trials: Cirrhosis Portal
Cirrhosis
Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents
Coated stents with different diameters are presently commercially available, but clinical studies on the assessment of the best stent diameter for a better clinical efficacy, a reduced number of complications, and an effective…
- Trial name
- NCT00401895
- Testing
- TIPS created with 8 or 10 mm covered stent
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- University of Roma La Sapienza
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Cirrhosis, Liver, End Stage Liver DIsease
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
Remote healthcare monitoring for cirrhosis has shown promise in overcoming barriers to accessing specialty care, improving healthcare quality, and reducing mortality.
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Symptoms and Signs, Physical Inactivity
- Trial name
- NCT06136221
- Testing
- LiverWatch Intervention
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- University of Pennsylvania
Liver Fibrosis, Hepatic Fibrosis
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response…
- Conditions
- Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
- Trial name
- POLT-HCV-SVR (NCT02138253)
- Testing
- IDN-6556
- Where
- 35 sites in United States
- Volunteers
- 64 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatic Encephalopathy
Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy
The purpose of this study is to compare a normal-protein diet containing branched-chain amino acids to a low-protein diet in patients with non-terminal cirrhosis (MELD < 25) who have developed an episode of hepatic encephalopathy…
- Trial name
- NCT00955500
- Testing
- Branched-chain amino acids, Maltodextrin
- Where
- 3 sites in Spain
- Volunteers
- 116 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Chronic Hepatitis C, Cirrhosis
Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
The purpose of this study is to evaluate the effects of sustained virological response in liver and spleen stiffness in patients with HCV compensated advanced chronic liver disease treated with new all oral antiviral drugs in…
- Conditions
- Chronic Hepatitis C, Cirrhosis, Portal Hypertension
- Trial name
- SPLEEN-C (NCT02439567)
- Testing
- Fibroscan: Liver and Spleen elastography
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Portal Hypertension Related to Cirrhosis, Esophageal Varices
2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices
The primary objective of this study is to evaluate the role of spleen shear wave elastography (SWE-SSM) for ruling in and ruling out clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic…
- Trial name
- NCT07122622
- Where
- Italy
- Volunteers
- 450 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Portal Hypertension
Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis
Investigate vasoactive medicators in portal hypertension on stored sera
- Trial name
- NCT00163631
- Where
- Australia
- Sponsor
- Bayside Health
Cirrhosis
Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
The main objective of the study will determine if patients with liver cirrhosis, anticoagulation free survival improves hypertension decompensation portal and / or transplantation without serious side effects.
- Trial name
- CIRROXABAN (NCT02643212)
- Testing
- Rivaroxaban
- Where
- 14 sites in Spain
- Volunteers
- 160 people
- Sponsor
- David Garcia Cinca
Portal Hypertension, Chronic Liver Disease (CLD)
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG
The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative…
- Conditions
- Portal Hypertension, Chronic Liver Disease (CLD), Cirrhosis
- Trial name
- EUS-PPG (NCT06863012)
- Testing
- Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement, Hepatic Venous Pressure Gradient (HVPG) Measurement
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
Liver Cirrhosis, Portal Hypertension.
Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
In the genesis and maintenance of PH associated with liver cirrhosis are two mechanisms that act synergistically. The first is an increase in hepatic vascular resistance, due in part to the disruption of liver structure inherent…
- Trial name
- SIMBETA (NCT01282385)
- Testing
- Simvastatin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hepatic Impairment, Cirrhosis
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
- Conditions
- Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
- Trial name
- NCT05045482
- Testing
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Liver Diseases, Liver Cirrhosis
Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)
The purpose of the study is to determine the role of new biomarkers in the diagnosis of sepsis in critically-ill patients with liver failure and to correlate the prognosis of these patients with parameters of endothelial function…
- Conditions
- Liver Diseases, Liver Cirrhosis, Sepsis, Critical Illness
- Trial name
- SELLIFA (NCT00488917)
- Where
- Belgium
- Volunteers
- 167 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Liver Cirrhoses
"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt
The informed consent will be obtained from the participants in the study. The study will be conducted on indoor patients, Department of Hepatology ILBS, New Delhi.
- Trial name
- NCT04089878
- Testing
- Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration, Standard Medical Treatment
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Ascites Hepatic
Empagliflozin as a Novel Therapy in Refractory Ascites
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients…
- Trial name
- NCT05430243
- Testing
- Empagliflozin 10 MG, Diuretics
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Alexandria University
Liver Cirrhoses
Preoperative Portal and Splanchnic Flow Measurement Using MRI
This study aims to assess the alteration of portal and splanchnic flow using MRI after liver transplantation in patients with splenomegaly or splenic varix.
- Trial name
- NCT03868397
- Testing
- Liver MRI
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Liver Cirrhosis, Portal Hypertension
Value of Von Willebrand Factor in Portal Hypertension
In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear.
- Trial name
- NCT01358123
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Portal Vein Thrombosis, Liver Cirrhosis
Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis
Portal vein thrombosis (PVT) is prevalent among patients with cirrhosis, and its prevalence rises with the severity of liver disease.
- Trial name
- NCT06818279
- Testing
- Dabigatran, Enoxaparin
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Ascites
Sodium Restriction in the Management of Cirrhotic Ascites
To determine the relationship between degree of sodium restriction and dietary compliance with clinical outcome of diuresis of portal hypertensive ascites in cirrhotic patients from a county hospital population.
- Trial name
- NCT00548366
- Testing
- Sodium restriction
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Texas Southwestern Medical Center
Primary Biliary Cholangitis, Liver Cirrhosis
Austrian PBC Registry
The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden.
- Conditions
- Primary Biliary Cholangitis, Liver Cirrhosis, Portal Hypertension
- Trial name
- PBC-AUT (NCT07598669)
- Where
- 11 sites in Austria
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna